# Why glucose averages leave a combination safety question open

- Article ID: research-316
- Product: RETA / IGF-1 LR3 (reta-igf-1-lr3-710, reta-igf-1-lr3-711)
- Canonical page: https://heritagebiolabs.com/research-library/articles/316-why-glucose-averages-leave-a-combination-safety-question-open
- Product collection: https://heritagebiolabs.com/research-library/products/reta-igf-1-lr3
- Product page: https://heritagebiolabs.com/product/reta-igf-1-lr3-710
- Product page: https://heritagebiolabs.com/product/reta-igf-1-lr3-711
- Reading focus: Interpreting evidence (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 1997, 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds. They can carry signals about nutrients or growth by acting on receptors. Retatrutide is an investigational peptide that activates GIP, GLP-1 and glucagon receptors. IGF-1 LR3 is a modified growth-factor protein with an extended amino-acid sequence. A clinical trial of retatrutide and older evidence on growth-factor signaling show why a lower average glucose measurement cannot establish the safety of the named pair. [1, 2, 3]

In the 2026 TRANSCEND-T2D-1 trial, researchers enrolled adults with type 2 diabetes whose glucose was above target with diet and exercise alone. Over 40 weeks, HbA1c fell more in the retatrutide groups than with placebo. HbA1c reflects average glucose exposure. A result on that measure does not reveal the number, timing or severity of episodes when glucose was unusually low. Investigators collect those outcomes separately. [1]

An FDA label for mecasermin, a recombinant form of human IGF-1, describes hypoglycemia as a risk for that product. Mecasermin and IGF-1 LR3 have different molecular identities. The mecasermin label therefore provides context about why researchers track glucose events when studying growth-factor signaling. It cannot supply a safety rate or establish how IGF-1 LR3 would behave in the presence of retatrutide. [2, 3]

A trial designed to assess the pair would need to distinguish a change in average glucose from episodes of low glucose. It would also have to record which intervention participants received and how the groups differed. The available clinical result described here concerns retatrutide under its own protocol, and the cited safety information concerns a different growth-factor product. Those sources answer separate questions. [1, 2, 3]

## Sources

1. H. S. Bajaj et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. The Lancet (publication 2026-06-06). <https://pubmed.ncbi.nlm.nih.gov/42250575/>
2. U.S. Food and Drug Administration. INCRELEX (mecasermin) injection, prescribing information. Drugs@FDA (publication 2025-07). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021839s033lbl.pdf>
3. V. Dunaiski et al. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs. Journal of Endocrinology (publication 1997-12). <https://pubmed.ncbi.nlm.nih.gov/9488001/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 064 - RETA IGF-1 LR3.docx; article 316; content SHA-256 4799970644a8bd02ade76b0e78c76962a5d1a7480a5bbcb8565339330cce16d9.
